Two-year toxicity of simultaneous integrated boost in hypofractionated prone breast cancer irradiation: Comparison with sequential boost in a randomized trial.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 33617910.
- Also identified by DOI 10.1016/j.radonc.2021.02.010.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A simultaneous integrated boost (SIB) leads to less acute toxicity. Less is known for late toxicity due to SIB. In this first and only randomized trial, two-years toxicity is analysed. Physician-assessed toxicity, using the LENT SOMA scale, and photographs, analysed with the BCCT.core software, was examined for 150 patients, randomized between SIB and sequential boost (SEB). Differences in physician-assessed two-years toxicity and photographic analysis between SIB and SEB are very small and not significant. There is no indication that a SIB leads to an excess in toxicity or worse cosmetic outcome at 2 years.
Medical subject headings
- Breast Neoplasms
- Radiotherapy, Intensity-Modulated